Comment 75 of 139, added on May 26th, 2013 at 10:43 AM.
Keegan Bradley has 3-stroke lead at Nelson - USA Today
Stocks continued their climb into uncharted territory on Friday, racking up
the fourth week in a row of gains as encouraging economic data prompted
investors to buy shares of growth companies.
The Dow Jones industrial average and the Standard & Poor¡¯s 500-stock index
finished at highs, driven by gains in energy and industrial shares. The
indexes have pushed to a series of high levels as part of the rally that
has lifted equities more than 16 percent for the year so far.
The Dow Jones industrial average gained 121.18 points, or 0.80 percent, to
close at a milestone 15,354.40. The S.& P. 500-stock index rose 17 points,
or 1.03 percent, to end at a record 1,667.42.
The Nasdaq composite index climbed 33.73 points, or 0.97 percent, to finish
at 3,498.97 ¡ª its highest close since October 2000.
In a sign of how far the market has come, the S.& P. 500 is about 1,000
points above the low it hit in March 2009 in the wake of the credit crisis
¡°It¡¯s hard to hold this market down,¡± said Michael Sheldon, chief market
strategist at RDM Financial in Westport, Conn.
Data released on Friday showed Americans felt better about their economic
and financial prospects in early May, with consumer sentiment at its
highest in nearly six years, while a gauge of future economic activity rose
in April to a near five-year high.
¡°If you believe the economy is going to gradually get better and that
global growth will improve, the parts of the market that have not benefited
so far, like cyclicals, will probably be the next group to outperform,¡±
Mr. Sheldon said. Cyclical industries are those that do well when times are
good, like an airline that benefits from more people flying on vacation.
The S.& P. energy sector index gained 0.8 percent, with Exxon Mobil up 1.2
percent at $91.76.
Boeing shares led the S.& P. 500¡¯s industrial sector index higher with a
2.4 percent advance to $98.92, its highest since October 2007. The S.& P.
industrial index rose 1.4 percent.
The rate of growth in the economy has been expected to slow in the second
quarter as tighter fiscal policy started to take effect. But recent
improvements, including in the labor market and retail sales, suggest the
recovery remains resilient.
¡°We are still recovering,¡± said Doreen Mogavero, chief of Mogavero, Lee &
Company in New York, who also noted that the comeback was slow. She added
that markets in the United States, for all their troubles, were ¡°still the
best place to be at this moment.¡±
Earlier in Friday¡¯s session, the Dow touched a high at 15,357.40. For the
week, the Dow advanced 1.7 percent, while the S.& P. 500 climbed 2.1
percent and the Nasdaq rose 1.9 percent.
J. P. Morgan raised its year-end target for the S.& P. 500 to 1,715 from
1,580, implying a gain of just under 3.5 percent for the index for the rest
of the year.
¡°We realize investors are apprehensive about making fresh money purchases,
but we see the risk/reward as particularly attractive in technology, health
care and financials,¡± said the client note from Thomas Lee, J. P.
Morgan¡¯s United States equity strategist.
J. C. Penney shares lost 4.2 percent to $18.01 after the retailer reported
another steep quarterly loss on weak sales and heavy clearance deals, and
the chief executive, Myron Ullman, cautioned that he needed time to fix the
Tableau Software, a maker of data analysis software, surged in its first
day of trading as investors bet the rising interest in Big Data would drive
its growth. Tableau surged 64 percent to $50.75.
The price of the benchmark 10-year Treasury note fell 22/32 to 98 5/32,
increasing the yield to 1.95, from 1.88 on Thursday.
Comment 74 of 139, added on May 26th, 2013 at 8:02 AM.
Orion Photo Reveals Spectacular Fiery Ribbon - iTechPost
The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223
dichloride) to treat men with symptomatic late-stage (metastatic)
castration-resistant prostate cancer that has spread to bones but not to
other organs. It is intended for men whose cancer has spread after
receiving medical or surgical therapy to lower testosterone.
Prostate cancer forms in a gland in the male reproductive system found
below the bladder and in front of the rectum. The male sex hormone
testosterone stimulates the prostate tumors to grow. According to the
National Cancer Institute, an estimated 238,590 men will be diagnosed with
prostate cancer and 29,720 will die from the disease in 2013.
Xofigo is being approved more than three months ahead of the product¡¯s
prescription drug user fee goal date of Aug. 14, 2013, the date the agency
was scheduled to complete review of the drug application. The FDA reviewed
Xofigo under the agency¡¯s priority review program, which provides for an
expedited review of drugs that appear to provide safe and effective therapy
when no satisfactory alternative therapy exists, or offer significant
improvement compared to marketed products.
¡°Xofigo binds with minerals in the bone to deliver radiation directly to
bone tumors, limiting the damage to the surrounding normal tissues,¡± said
Richard Pazdur, M.D., director of the Office of Hematology and Oncology
Products in the FDA¡¯s Center for Drug Evaluation and Research. ¡°Xofigo is
the second prostate cancer drug approved by the FDA in the past year that
demonstrates an ability to extend the survival of men with metastatic
In August 2012, the FDA approved Xtandi to treat men with metastatic
castration-resistant prostate cancer that has spread or recurred, even with
medical or surgical therapy to minimize testosterone. Xtandi is approved
for patients who have previously been treated the chemotherapy drug
Xofigo¡¯s safety and effectiveness were evaluated in a single clinical
trial of 809 men with symptomatic castration-resistant prostate cancer that
spread to bones but not to other organs. Patients were randomly assigned to
receive Xofigo or a placebo plus best standard of care.
The study was designed to measure overall survival. Results from a
pre-planned interim analysis showed men receiving Xofigo lived a median of
14 months compared to a median of 11.2 months for men receiving placebo. An
exploratory updated analysis conducted later in the trial confirmed
Xofigo¡¯s ability to extend overall survival.
The most common side effects reported during clinical trials in men
receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg,
ankle or foot. The most common abnormalities detected during blood testing
included low levels of red blood cells (anemia), lymphocytes
(lymphocytopenia), white blood cells (leukopenia), platelets
(thrombocytopenia) and infection-fighting white blood cells (neutropenia).